Mirum Pharmaceuticals Inc expected to post a loss of 47 cents a share - Earnings Preview

Mirum Pharmaceuticals

06/08/2024 03:24

* Mirum Pharmaceuticals Inc  MIRM.OQ   MIRM.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 7
for the period ending June 30 2024
    * The Foster City California-based  company is expected to
report
a 100.7% increase in revenue to $75.246 million from $37.5
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Mirum Pharmaceuticals
Inc is
for a loss of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mirum
Pharmaceuticals Inc is $63.00​, above​ its last closing price
of $38.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.48       -0.48      -0.54     Missed  -12.7
 Dec. 31 2024  -0.24       -0.24      -0.66     Missed  -171.6
 Sep. 30 2023  -0.63       -0.63      -0.57     Beat    9.3​
 Jan. 1 0001   -0.81       -0.80      -1.94     Missed  -143.9
 ​​Mar.        -0.96       -0.94      -0.80     Beat    14.7
 31 2023                                                
 Dec. 31 2022  -1.01       -1.02      -0.99     Beat    2.9​
 Jan. 1 0001   -1.10       -1.07      -1.02     Beat    4.6
 Jan. 1 0001   -1.03       -1.15      -0.84     Beat    27.2
 This summary was machine generated August 6 at 02:23 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)